ArticleCell death discovery2025

Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment.

Lin Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.